Fixed-combination brimonidinetimolol versus latanoprost in glaucoma and ocular hypertension: A 12-week, randomized, comparison study

Current Medical Research and Opinion

Volumn 28, Issue 5, 2012, Pages 781-788

  Katz, L Jay ^a   Rauchman, Steven H ^b   Cottingham, Andrew J ^c   Simmons, Steven T ^d   Williams, Julia M ^e   Schiffman, Rhett M ^e   Hollander, David A ^e  

^a WILLS EYE HOSPITAL   (United States)

^b North Valley Eye Medical Group   (United States)

^c Division of iVitalize   (United States)

^d Glaucoma Consultants of the Capital Region   (United States)

^e ALLERGAN INC   (United States)

Author keywords

Alpha adrenergic agonist; Beta blocker; Fixed combination; Glaucoma; Intraocular pressure (IOP); Prostaglandin analog

Indexed keywords

BRIMONIDINE PLUS TIMOLOL; LATANOPROST; ANTIHYPERTENSIVE AGENT; BRIMONIDINE; EYE DROPS; PROSTAGLANDIN F; QUINOXALINE DERIVATIVE; TIMOLOL;

ADULT; ARTICLE; BIOMICROSCOPY; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FEMALE; FOLLOW UP; GLAUCOMA; HEART MUSCLE ISCHEMIA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; TIME FACTORS; TIMOLOL; TREATMENT OUTCOME;

EID: 84861139020     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.681036     Document Type: Article

References (20)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13 (Pubitemid 34620348)
2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
3. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53 (Pubitemid 33032760)
4. Hedman K, Alm A. A pooled-data analysis of three randomized, doublemasked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104 (Pubitemid 30439106)
5. Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84 (Pubitemid 32904567)
6. Higginbotham EJ, Schuman JS, Goldberg I, et al., for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-93 (Pubitemid 36105433)
7. van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressurelowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85 (Pubitemid 40916921)
8. Stewart WC, Konstas AG, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-22
9. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6 (Pubitemid 43875566)
10. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14 (Pubitemid 29315757)
11. Goñi FJ, for the Brimonidine/Timolol Fixed Combination Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90 (Pubitemid 41426417)
12. Sherwood MB, Craven ER, Chou C, et al., for the Combigan Study Groups I and II. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8 (Pubitemid 44379855)
13. Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma 2008;17:674-9
14. Chauhan BC, Mikelberg FS, Artes PH, et al., for the Canadian Glaucoma Study Group. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 2010;128:1249-55
15. Nixon DR, Yan DB, Chartrand J-P, et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin 2009;25:1645-53
16. Le Henanff A, Giraudeau B, Baron G, et al. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006;295:1147-51 (Pubitemid 43352344)
17. Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin 2008;24: 2663-7
18. WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55 (Pubitemid 33035282)
19. Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009; 127:402-6
20. Krupin T, Liebmann JM, Greenfield DS, et al., on behalf of the Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151:671-81